Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted May 14, 2008
DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005)
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Member Program Contributor
key implications: Less reimbursements for DEXA may lead to less testing, as cost of leasing equipment will be greater then revenue derived form procedures However, Less revenue/procedure could lead to greater utilization of equipment to cover costs involved and result in earlier testing of women...
Posted May 12, 2008
Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS)
Analysis of: Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS) | pharmalive.com
Author: GLG Member Program Contributor
THE IMPLICATIONS HAVE TO DO WITH THE AVAILABILITY OF A PRODUCT THAT BRIDGES THE GAP OF INSULIN THERAPY IN THOSE THAT REQUIRE IT  AND STILL WILL NOT USE INJECTABLE INSULIN.
Posted May 6, 2008
Government Cuts in Funding for DXA in Physicians' Offices May Lead to Difficulties for Rural Patients
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: William Fink, President Managed Care Pharmacy Consultants, Inc
It is well known that millions of people in the US suffer from osteoporosis which leads directly to debilitating fractures.   Early diagnosis of osteoporosis and low bone mass will help prevent chronic pain and loss of independence.  Once diagnosed, treatment is readily available and...
Posted April 21, 2008
Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Osteoporosis is a major issue in the aging population. Fractures of the hip and spine can be catastrophic occurrences for the elderly as even with surgical and image guided treatment, the ensuing morbidity can alter a patients life style. Reducing osteoporosis can reduce medical costs but preventing...
Posted April 21, 2008
Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Aclasta, an IV bisphosponate known generically as zoledronic acid, seems to do one thing consistently: it has an uncanny knack for showing an absolute risk reduction of about 1-2% in whatever endpoint is being measured, and against whatever control it faces head-to-head.  It has been shown to have...
Posted April 21, 2008
Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Reclast will make life much easier for patients with osteoporosis. This study strenghtens this oncept. The ig problem is coverage. Ther is still a lag between the data and payors. Once this is resolved use of Reclast will be the way to go.
Eric Gruff Posted April 16, 2008
AtheroGenics' AGI-1067 Shows Some Promise, But There Are Still Questions
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: Eric Gruff, Principal E4 Consulting
The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.
Posted April 14, 2008
Amgen Drug Helps Bones
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
Postmenopausal osteoporosis is a real problem for a huge number of the older aged patients, and the population is aging. In daily orthopaedic praxis, I see a lot of osteoporosis related fractures of the wrist, the hip, and the vertebral column. Just yesterday, I operated a pseudarthrosis in the femoral...
Posted April 9, 2008
New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Member Program Contributor
The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...
Posted April 9, 2008
Taranabant looks promising
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
Merck's endocannabinoid inverse agonist (CB1R )recently completed a 52 wk trial in which 2000 subjects were randomized to placebo, 2, 4, or 6 mg of taranabant.  Before the trial ended, the 6 mg dosed subjects had to be rerandomized to placebo or 4 mg due to toxicity.  The...
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 315

GLG News: What Experts Think Is Important





Analytics